PharmaEssentia Corporation (TPE:6446)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
1,025.00
-55.00 (-5.09%)
Jul 30, 2026, 1:30 PM CST

PharmaEssentia Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
5,9315,0452,966-623.84-1,375-2,811
Depreciation & Amortization
371.39351.55336.99250.58225.38226
Other Amortization
47.7447.0530.7218.182.541.09
Loss (Gain) From Sale of Assets
1.52.030.93-0.10.07
Loss (Gain) on Equity Investments
6.654.46----
Stock-Based Compensation
483.38463.47164.39710.21216.21501.52
Other Operating Activities
-262.25-302.77-275.6-383.62-464.9311.18
Change in Accounts Receivable
-1,869-1,849-1,312-513.66-332.6-15.45
Change in Inventory
164.39-62.2125.34-356.61-240.66-466.53
Change in Accounts Payable
-44.8630.27-2.44-102.0554.62-0.69
Change in Unearned Revenue
0.07-0.230.23---
Change in Other Net Operating Assets
1,1211,547590.17291.29408.6891.74
Operating Cash Flow
5,9515,2782,525-709.51-1,505-2,462
Operating Cash Flow Growth
52.99%109.04%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2,262-1,911-862-1,286-312.03-70.33
Sale (Purchase) of Intangibles
-14.45-12.51-41.49-41.65-8.72-27.54
Investment in Securities
-376.32-440.1-423.65-96--25
Other Investing Activities
-64.09-111.32-7.76937.04-922.0744.7
Investing Cash Flow
-2,716-2,475-1,335-486.65-1,243-78.18

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-2,243-1973.88-
Total Debt Issued
2,2432,243-1973.88-
Short-Term Debt Repaid
--2,243-21-973.88--30
Long-Term Debt Repaid
--229.31-233.12-150.97-127.41-116.23
Total Debt Repaid
-2,469-2,472-254.12-1,125-127.41-146.23
Net Debt Issued (Repaid)
-226.96-229.31-254.12-1,124846.47-146.23
Issuance of Common Stock
125.2395.5591.114,3308,7433,045
Repurchase of Common Stock
----2,718--87.5
Common Dividends Paid
-366.17-366.17----
Other Financing Activities
----34.56-10.26-2.41
Financing Cash Flow
-467.91-499.93-163.0210,4549,5792,809

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-625.14-660.75358.27104.1119-15.25
Net Cash Flow
2,1411,6421,3859,3626,850253.27

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,6893,3661,663-1,996-1,818-2,532
Free Cash Flow Growth
25.30%102.47%----
Free Cash Flow Margin
21.08%21.53%17.08%-39.09%-63.06%-385.74%
Free Cash Flow Per Share
8.958.184.04-5.03-5.20-7.91
Levered Free Cash Flow
2,2162,12621.42-1,292-2,589-1,316
Unlevered Free Cash Flow
2,2312,14235.29-1,263-2,577-1,310

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
24.8425.5322.1934.5610.262.41
Cash Income Tax Paid
182.73232.89297.976.875.68-0
Change in Working Capital
-629.1-333.28-698.22-681.02-109.97-390.93